August 26, 2020,Dermavant Sciences announce,The company's fastest-growing product Tapinarof (DMVT-505) (1% cream formulation),Two multicenter, randomized, double-blind, blank matrix-controlled Phase 3 clinical trials named PSOARING 1 and PSOARING 2 for the indications of adult plaque psoriasis reached the primary endpoint.
Tapinarof is an investigational therapeutic aromatic receptor modulator (TAMA) that can be used to treat psoriasis and atopic dermatitis (AD). Tapinarof can regulate the activity of lymphocyte tyrosine kinases and aromatic hydrocarbon receptors, and inhibit the production of inflammatory cytokines in psoriasis, the infiltration of inflammatory cells, the abnormal proliferation of keratinocytes, and the formation and proliferation of blood vessels.
2020-09-02
